SL Science Holding Ltd（SLBT）の株式分析SLBTSL Science Holding Ltd

SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities. It operates in the Healthcare sector.

SL Science Holding Ltd (SLBT) is not a good buy right now due to significant financial instability and poor performance metrics. The current price is $1.51, and the company has reported a staggering year-to-date change of -73.97%. Additionally, the current ratio has dropped to 0.00, indicating severe liquidity issues, and the forward P/E ratio is 0, suggesting no earnings expectations. The main risk is the high debt-to-equity ratio of 882.89%, which poses a serious threat to financial stability.